


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 016325-008110US

Mail Stop Amendment
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

On February 7, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: 
Anna C. Kundel

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JOHNSON et al.

Application No.: 10/805,075

Filed: March 19, 2004

For: COMPOSITIONS AND METHODS
OF USING HEXOKINASE V

Examiner: Not yet assigned

Art Unit: 1635

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:ack
60412778 v1



Substitute for form 1449A/PTO

(use as many sheets as necessary)

Application Number	10/805,075
Filing Date	March 19, 2004
First Named Inventor	Johnson, Jeffrey D.
Art Unit	1635
Examiner Name	Not yet assigned
Attorney Docket Number	016325-008110US

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/805,075	
			Filing Date	March 19, 2004	
			First Named Inventor	Johnson, Jeffrey D.	
			Art Unit	1635	
			Examiner Name	Not yet assigned	
Sheet	2	of	2	Attorney Docket Number	016325-008110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A3	BECKER, T., et al., "Overexpression of Hexokinase I in Isolated Islets of Langerhans via Recombinant Adenovirus," <u>The Journal of Biological Chemistry</u> , August 1994, pp. 21234-21238, Vol. 269, No. 33, U.S.A.	
	A4	CHRISTESEN, H., et al., "The Second Activating Glucokinase Mutation (A456V)," <u>Diabetes</u> , April 2002, pp. 1240-1246, Vol. 51.	
	A5	FROGUEL, P., et al., "Familial Hyperglycemia Due To Mutations in Glucokinase: Definition of a Subtype of Diabetes Mellitus," <u>The New England Journal of Medicine</u> , March 11, 1993, pp. 697-702, Vol. 328, No. 10.	
	A6	GLASER, B., et al., "Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation," <u>The New England Journal of Medicine</u> , January 22, 1998, pp. 226-230, Vol. 338, No. 4.	
	A7	HOSOKAWA, H., et al., "Upregulated Hexokinase Activity in Isolated islets from Diabetic 90% Pancreatectomized Rats," <u>Diabetes</u> , November 1995, pp. 1328-1333, Vol. 44.	
	A8	MATSCHINSKY, F., "Regulation of Pancreatic β -Cell Glucokinase," <u>Diabetes</u> , December 2002, pp. S395-S403, Vol. 51, Supplement 3.	
	A9	MILBURN, J., et al., "Pancreatic β -Cells in Obesity," <u>The Journal of Biological Chemistry</u> , January 1995, pp. 1295-1299, Vol. 270, No. 3, U.S.A.	
	A10	NJOLSTAD, P., et al., "Neonatal Diabetes Mellitus Due to Complete Glucokinase Deficiency," <u>The New England Journal of Medicine</u> , May 24, 2001, pp. 1588-1592, Vol. 344, No. 21.	
	A11	SCHUIT, F., et al., "Cellular Origin of Hexokinase in Pancreatic Islets," <u>The Journal of Biological Chemistry</u> , November 1999, pp. 32803-32809, Vol. 274, No. 46, U.S.A.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.